Zobrazeno 1 - 10
of 75
pro vyhledávání: '"Angel Guerrero Zotano"'
Autor:
Andres Poveda, Ana Oaknin, Ignacio Romero, Angel Guerrero-Zotano, Lorena Fariñas-Madrid, Victor Rodriguez-Freixinos, Pedro Mallol, Raquel Lopez-Reig, Jose Antonio Lopez-Guerrero
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-11 (2021)
Abstract The poly (ADP-Ribose) polymerase (PARP) inhibitor olaparib has shown antitumor activity in patients with ovarian or breast cancer with or without BRCA1/2 mutations. Lurbinectedin is an ecteinascidin that generates DNA double-strand breaks. W
Externí odkaz:
https://doaj.org/article/d1515ed3222c482292aa0ffa3a73aad2
Autor:
Frankie A. Holmes, Beverly Moy, Suzette Delaloge, Stephen K.L. Chia, Bent Ejlertsen, Janine Mansi, Hiroji Iwata, Michael Gnant, Marc Buyse, Carlos H. Barrios, Tajana Silovski, Robert Šeparović, Anna Bashford, Angel Guerrero Zotano, Neelima Denduluri, Debra Patt, Erhan Gokmen, Ira Gore, John W. Smith, Sibylle Loibl, Norikazu Masuda, Zorica Tomašević, Katarina Petráková, Daniel DiPrimeo, Alvin Wong, Miguel Martin, Arlene Chan
Publikováno v:
European Journal of Cancer. 184:48-59
ExteNET showed that neratinib, an irreversible pan-HER tyrosine ki- nase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved inva- sive disease-free survival in women with early-stage HER2-positive breast cancer. We rep
Autor:
Virginia Lope, Angel Guerrero-Zotano, Emma Ruiz-Moreno, Begoña Bermejo, Silvia Antolín, Álvaro Montaño, José Manuel Baena-Cañada, Manuel Ramos Vázquez, Nerea Fernández de Larrea-Baz, José Ignacio Chacón, José Angel García-Sáenz, Clara Olier, Montserrat Muñoz, Antonio Antón, Pedro Sánchez Rovira, Angels Arcusa Lanza, Sonia González, Amparo Oltra, Joan Brunet, Joaquín Gavilá Gregori, María Teresa Martínez, Lourdes Calvo, Libertad Rosell, Susana Bezares, Roberto Pastor-Barriuso, Beatriz Pérez-Gómez, Miguel Martín, Marina Pollán
Publikováno v:
Cancers, Vol 14, Iss 19, p 4705 (2022)
Breast cancer (BC) survivors are advised to follow the WCRF/AICR cancer prevention recommendations, given their high risk of developing a second tumour. We aimed to explore compliance with these recommendations in BC survivors and to identify potenti
Externí odkaz:
https://doaj.org/article/74efbdccd0e148af99a4b0494bba2f14
Autor:
Silvia Antolin Novoa, César A Rodríguez, Josefina Cruz, Sara López-Tarruella, Ariadna Tibau, Encarna Adrover, Ana Miguel, Mireia Margelí, Purificación Martínez, María Hernández, Antonio Antón, Álvaro Rodríguez-Lescure, Catalina Falo, Isabel Álvarez, Diego Malón, Raquel Andrés, José L Alonso-Romero, César Gómez, J. José Illaramendi, Ruth Campo, Juan José Miralles, Susana Bezares, Federico Rojo, Angel Guerrero-Zotano
Publikováno v:
Cancer Research. 83:P4-07
Background: Triple negative breast cancer (TNBC) is well known for its more aggressive course and poorer prognosis compared to other BC subtypes. RegistEM study provides real world data to understand the distribution of BC subtypes in the advanced se
Autor:
Isabel Álvarez, Angel Guerrero-Zotano, Ariadna Tibau, Catalina Falo, María Hernández, Ana Miguel, Raquel Andrés, Álvaro Rodríguez-Lescure, Miguel Corbellas, Sara López-Tarruella, Purificación Martínez, Cesar A Rodríguez, Diego Malón, María Marin, Mª José Echarri, Antonio Antón, Josefina Cruz, Diana Moreno, J. Ignacio Chacón, Ruth Campo, Andrea Blasco, Susana Bezares, Federico Rojo, Silvia Antolin
Publikováno v:
Cancer Research. 83:P4-07
Background: HER2-low breast cancer (BC) is a new therapeutic entity, but it is uncertain if this subgroup of BC differs from HER2-negative tumors in clinical characteristics, prognosis, and response to therapy. The objective is to describe the clinic
Autor:
Sara López-Tarruella, Angel Guerrero-Zotano, Josefina Cruz, Silvia Antolin Novoa, Purificación Martínez, María Hernández, César A Rodríguez, J. Ignacio Chacón, Ariadna Tibau, Catalina Falo, Álvaro Rodríguez-Lescure, Mireia Margelí, Sonia Servitja, Raquel Andrés, María Galán-Gramaje, Encarna Adrover, Ana Miguel, Rafael Villanueva, Silvia Varela, Ruth Campo, Mª José Escudero, Susana Bezares, Federico Rojo, Isabel Álvarez
Publikováno v:
Cancer Research. 83:P4-07
Background: Over the last years, the treatment of HER2-positive (HER2+) breast cancer (BC) patients (pts) has been changing because of the development of new anti-HER2 agents. In the current analysis, we describe the features, treatment patterns, pro
Autor:
Martine J. Piccart, David Venet, Matteo Benelli, Lucy R. Yates, Florentine S. Hilbers, Carmela Caballero, Andrea Vingiani, Mariana Brandão, Maite Lasa Montoya, Nadia Harbeck, David A. Cameron, Susan Knox, Sherene Loi, Philippe L. Bedard, Oskar Th Johannsson, Nancy E. Davidson, Gabriele Zoppoli, Barbro Linderholm, Sibylle Loibl, Ethel Seyll, Marta Paoli, Ásgerdur Sverrisdóttir, Richard Greil, Silvia Khodaverdi, Martina Degiorgis, Karolina Fs Larsson, Andrea Bonetti, Peter Hall, Angel Guerrero-Zotano, Hans Wildiers, Andrea Gombos, Beatriz Rojas, Dario Romagnoli, Sandrine Marreaud, Caroline Duhem, Joan Albanell, Fatima Cardoso, Marija Balic, Marco Colleoni, Jorge S. Reis-Filho, Judith M. Bliss, Giuseppe Curigliano, Elsemieke D. Scheepers, Giuseppe Viale, Evandro de Azambuja, Eva M. Ciruelos, Angelo Di Leo, Justin Ndozeng, Mark E. Robson, Einav Nili Gal-Yam, Christos Sotiriou, Debora Fumagalli, Alexandre Irrthum, Mafalda Oliveira, Philippe Aftimos
AURORA aims to study the processes of relapse in metastatic breast cancer (MBC) by performing multi-omics profiling on paired primary tumors and early-course metastases. Among 381 patients (primary tumor and metastasis pairs: 252 targeted gene sequen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64ba8398f27bd01926989bb92cec09d4
https://doi.org/10.1158/2159-8290.c.6549478.v1
https://doi.org/10.1158/2159-8290.c.6549478.v1
Autor:
Martine J. Piccart, David Venet, Matteo Benelli, Lucy R. Yates, Florentine S. Hilbers, Carmela Caballero, Andrea Vingiani, Mariana Brandão, Maite Lasa Montoya, Nadia Harbeck, David A. Cameron, Susan Knox, Sherene Loi, Philippe L. Bedard, Oskar Th Johannsson, Nancy E. Davidson, Gabriele Zoppoli, Barbro Linderholm, Sibylle Loibl, Ethel Seyll, Marta Paoli, Ásgerdur Sverrisdóttir, Richard Greil, Silvia Khodaverdi, Martina Degiorgis, Karolina Fs Larsson, Andrea Bonetti, Peter Hall, Angel Guerrero-Zotano, Hans Wildiers, Andrea Gombos, Beatriz Rojas, Dario Romagnoli, Sandrine Marreaud, Caroline Duhem, Joan Albanell, Fatima Cardoso, Marija Balic, Marco Colleoni, Jorge S. Reis-Filho, Judith M. Bliss, Giuseppe Curigliano, Elsemieke D. Scheepers, Giuseppe Viale, Evandro de Azambuja, Eva M. Ciruelos, Angelo Di Leo, Justin Ndozeng, Mark E. Robson, Einav Nili Gal-Yam, Christos Sotiriou, Debora Fumagalli, Alexandre Irrthum, Mafalda Oliveira, Philippe Aftimos
File with the supplementary material & methods, supplementary tables and supplementary figure.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::39a107466be99e0e8d07f33aa5227fcd
https://doi.org/10.1158/2159-8290.22540795.v1
https://doi.org/10.1158/2159-8290.22540795.v1
Autor:
Martine J. Piccart, David Venet, Matteo Benelli, Lucy R. Yates, Florentine S. Hilbers, Carmela Caballero, Andrea Vingiani, Mariana Brandão, Maite Lasa Montoya, Nadia Harbeck, David A. Cameron, Susan Knox, Sherene Loi, Philippe L. Bedard, Oskar Th Johannsson, Nancy E. Davidson, Gabriele Zoppoli, Barbro Linderholm, Sibylle Loibl, Ethel Seyll, Marta Paoli, Ásgerdur Sverrisdóttir, Richard Greil, Silvia Khodaverdi, Martina Degiorgis, Karolina Fs Larsson, Andrea Bonetti, Peter Hall, Angel Guerrero-Zotano, Hans Wildiers, Andrea Gombos, Beatriz Rojas, Dario Romagnoli, Sandrine Marreaud, Caroline Duhem, Joan Albanell, Fatima Cardoso, Marija Balic, Marco Colleoni, Jorge S. Reis-Filho, Judith M. Bliss, Giuseppe Curigliano, Elsemieke D. Scheepers, Giuseppe Viale, Evandro de Azambuja, Eva M. Ciruelos, Angelo Di Leo, Justin Ndozeng, Mark E. Robson, Einav Nili Gal-Yam, Christos Sotiriou, Debora Fumagalli, Alexandre Irrthum, Mafalda Oliveira, Philippe Aftimos
Supplementary file with the listing of the liver genes excluded from transcriptomic analyses.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0539423b318b21e00fc900c99c0f983f
https://doi.org/10.1158/2159-8290.22540798.v1
https://doi.org/10.1158/2159-8290.22540798.v1
Autor:
Carlos L. Arteaga, Alan Auerbach, Richard Bryce, Alshad S. Lalani, Richard E. Cutler, Francesca Avogadri-Connors, Justin M. Balko, Melinda Sanders, Paula I. González Ericsson, Sarah Croessmann, Mellissa J. Nixon, Luigi Formisano, Angel Guerrero-Zotano, Luis J. Schwarz, Dhivya R. Sudhan
Purpose:The phase III ExteNET trial showed improved invasive disease-free survival in patients with HER2+ breast cancer treated with neratinib versus placebo after trastuzumab-based adjuvant therapy. The benefit from neratinib appeared to be greater
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccdef9da4b82af81bb809312ab12ea87
https://doi.org/10.1158/1078-0432.c.6529268.v1
https://doi.org/10.1158/1078-0432.c.6529268.v1